{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:16:25Z","timestamp":1769501785493,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"National Cancer Center Research and Development Fund","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"Applied Research for Innovative Treatment of Cancer","award":["H26-084"],"award-info":[{"award-number":["H26-084"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12957-016-1059-2","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T08:13:56Z","timestamp":1481184836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Kazuhiro","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Joyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Chuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiko","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunori","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Toguchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihide","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,8]]},"reference":[{"key":"1059_CR1","volume-title":"Bone Tumor Registry in JAPAN 2013","author":"Japanese Orthopaedic Association Musculoskeletal Tumor Committee","year":"2013","unstructured":"Japanese Orthopaedic Association Musculoskeletal Tumor Committee. Bone Tumor Registry in JAPAN 2013. Tokyo: National Cancer Center; 2013."},{"key":"1059_CR2","volume-title":"Soft Tissue Tumor Registry in JAPAN 2013","author":"Japanese Orthopaedic Association Musculoskeletal Tumor Committee","year":"2013","unstructured":"Japanese Orthopaedic Association Musculoskeletal Tumor Committee. Soft Tissue Tumor Registry in JAPAN 2013. Tokyo: National Cancer Center; 2013."},{"key":"1059_CR3","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1200\/JCO.2003.02.026","volume":"21","author":"J Weitz","year":"2003","unstructured":"Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21:2719\u201325.","journal-title":"J Clin Oncol"},{"key":"1059_CR4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0889-8588(18)30070-4","volume":"9","author":"GD Demetri","year":"1995","unstructured":"Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Hematol Oncol Clin North Am. 1995;9:765\u201385.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1059_CR5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","volume":"113","author":"N Pervaiz","year":"2008","unstructured":"Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573\u201381.","journal-title":"Cancer"},{"key":"1059_CR6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415\u201323.","journal-title":"Lancet Oncol"},{"key":"1059_CR7","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, et al. Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110\u20137.","journal-title":"Cancer Res"},{"key":"1059_CR8","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.1995.13.12.2865","volume":"13","author":"E Eisenhauer","year":"1995","unstructured":"Eisenhauer E. Docetaxel: current status and future prospects. J Clin Oncol. 1995;13:2865\u20138.","journal-title":"J Clin Oncol"},{"key":"1059_CR9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0959-8049(01)00408-7","volume":"38","author":"L Svancarova","year":"2002","unstructured":"Svancarova L, Blay JY, Judson I, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38:556\u20139.","journal-title":"Eur J Cancer"},{"key":"1059_CR10","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2000.18.10.2081","volume":"18","author":"J Verweij","year":"2000","unstructured":"Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first-line and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18:2081\u20136.","journal-title":"J Clin Oncol"},{"key":"1059_CR11","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ijc.21867","volume":"119","author":"JO Bay","year":"2006","unstructured":"Bay JO, Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer. 2006;119:706\u201311.","journal-title":"Int J Cancer"},{"key":"1059_CR12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2004.08.043","volume":"22","author":"KM Leu","year":"2004","unstructured":"Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22:1706\u201312.","journal-title":"J Clin Oncol"},{"key":"1059_CR13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00280-011-1742-5","volume":"69","author":"EM Lee","year":"2012","unstructured":"Lee EM, Rha SY, Lee J, et al. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Cancer Chemother Pharmacol. 2012;69:635\u201342.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1059_CR14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4143\/crt.2012.44.1.43","volume":"44","author":"HY Lee","year":"2012","unstructured":"Lee HY, Shin SJ, Kim HS, et al. Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. Cancer Res Treat. 2012;44:43\u20139.","journal-title":"Cancer Res Treat"},{"key":"1059_CR15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jjco\/hys030","volume":"42","author":"WX Qi","year":"2012","unstructured":"Qi WX, He AN, Tang LN, et al. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol. 2012;42:427\u201331.","journal-title":"Jpn J Clin Oncol"},{"key":"1059_CR16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1634\/theoncologist.2011-0467","volume":"17","author":"P Pautier","year":"2012","unstructured":"Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17:1213\u201320.","journal-title":"Oncologist"},{"key":"1059_CR17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2008.11.027","volume":"112","author":"ML Hensley","year":"2009","unstructured":"Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009;112:563\u20137.","journal-title":"Gynecol Oncol"},{"key":"1059_CR18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","volume":"109","author":"ML Hensley","year":"2008","unstructured":"Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008;109:323\u20138.","journal-title":"Gynecol Oncol"},{"key":"1059_CR19","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","volume":"25","author":"RG Maki","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25:2755\u201363.","journal-title":"J Clin Oncol"},{"key":"1059_CR20","first-page":"415","volume":"36","author":"T Schmitt","year":"2013","unstructured":"Schmitt T, Kosely F, Wuchter P, et al. Gemcitabine and docetaxel for metastatic soft tissue sarcoma\u2014a single center experience. Onkologie. 2013;36:415\u201320.","journal-title":"Onkologie"},{"key":"1059_CR21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7314\/APJCP.2012.13.2.463","volume":"13","author":"AO Kaya","year":"2012","unstructured":"Kaya AO, B\u00fcy\u00fckberber S, Ozkan M, et al. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev. 2012;13:463\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1059_CR22","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.ejca.2015.05.010","volume":"51","author":"EJ Davis","year":"2015","unstructured":"Davis EJ, Chugh R, Zhao L, et al. A randomised, open-label, phase II study of neo\/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. Eur J Cancer. 2015;51:1794\u2013802.","journal-title":"Eur J Cancer"},{"key":"1059_CR23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/annonc\/mdn705","volume":"20","author":"K Takeda","year":"2009","unstructured":"Takeda K, Negoro S, Tamura T, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol. 2009;20:835\u201341.","journal-title":"Ann Oncol"},{"key":"1059_CR24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jjco\/hyn153","volume":"39","author":"K Tanaka","year":"2009","unstructured":"Tanaka K, Kawamoto H, Saito I, et al. Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol. 2009;39:271\u20133.","journal-title":"Jpn J Clin Oncol"},{"key":"1059_CR25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jjco\/hyu220","volume":"45","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Mizusawa J, Fukuda H, et al. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol. 2015;45:555\u201361.","journal-title":"Jpn J Clin Oncol"},{"key":"1059_CR26","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jjco\/hyu080","volume":"44","author":"K Kataoka","year":"2014","unstructured":"Kataoka K, Tanaka K, Mizusawa J, et al. A randomized phase II\/III trial of perioperative chemotherapy with adriamycin plus ifosfamide vs gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group study JCOG1306. Jpn J Clin Oncol. 2014;44:765\u20139.","journal-title":"Jpn J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-016-1059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T06:05:54Z","timestamp":1568613954000},"score":1,"resource":{"primary":{"URL":"http:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-016-1059-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1186\/s12957-016-1059-2","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"306"}}